Eli Lilly Cash Flow Statement
NYSE: LLYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pre-market: 1,179.80 +0.04%
Eli Lilly free cash flow
In fiscal 2025, Eli Lilly generated $16.81 billion of operating cash flow and spent $7.84 billion on capital expenditures. That left free cash flow of $8.97 billion, a free-cash-flow margin of 13.8% of revenue. Free cash flow was up 138.6% from the prior year's $3.76 billion.
Eli Lilly returned $9.49 billion to shareholders: $5.38 billion in dividends and $4.11 billion in share repurchases, equal to 106% of free cash flow. Free cash flow covered dividend payments 1.7 times.
Summary generated from market data by MetaCap's automated system. Methodology
Eli Lilly cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 20.64B | 10.59B | 5.24B | 6.24B | 5.58B | 6.19B | 8.32B | 3.23B | -204.10M | 2.74B |
| Net Income growth (YoY) | +94.90% | +102.10% | -16.09% | +11.88% | -9.88% | -25.54% | +157.38% | — | -107.46% | +13.67% |
| Depreciation & Amortization | 2.00B | 1.77B | 1.53B | 1.52B | 1.55B | 1.32B | 1.23B | 1.61B | 1.57B | 1.50B |
| Stock-Based Compensation | 626.00M | 646.00M | 629.00M | 371.10M | 342.80M | 308.10M | 312.40M | 279.50M | 281.30M | 255.30M |
| Change in Working Capital | -8.09B | -5.38B | -3.06B | -800.00K | -1.01B | -1.07B | -1.47B | -2.25B | -284.70M | -179.30M |
| Operating Cash Flow | 16.81B | 8.82B | 4.24B | 7.59B | 7.37B | 6.50B | 4.84B | 5.52B | 5.62B | 4.85B |
| Capital Expenditures | -7.84B | -5.06B | -3.45B | -1.85B | -1.31B | -1.39B | -1.03B | -1.21B | -1.08B | -1.04B |
| Investing Cash Flow | -10.97B | -9.30B | -7.15B | -3.76B | -2.87B | -2.26B | -8.08B | 1.91B | -3.78B | -3.14B |
| Dividends Paid | -5.38B | -4.68B | -4.07B | -3.54B | -3.09B | -2.69B | -2.41B | -2.31B | -2.19B | -2.16B |
| Share Repurchases | -4.11B | -2.50B | -750.00M | -1.50B | -1.25B | -500.00M | -4.40B | -4.15B | -299.80M | -600.10M |
| Debt Issued | 13.17B | 11.42B | 3.96B | 0 | 2.41B | 2.06B | 6.56B | 2.48B | 2.23B | 1.21B |
| Debt Repaid | -778.00M | -664.00M | 0 | -1.56B | -1.91B | -276.50M | -2.87B | -1.01B | -630.60M | -200.00K |
| Financing Cash Flow | -2.21B | 1.23B | 3.50B | -5.41B | -4.13B | -3.14B | -2.32B | -5.90B | 142.60M | -559.80M |
| Net Change in Cash | 4.00B | 449.00M | 752.00M | -1.75B | 161.40M | 1.32B | -5.66B | 1.46B | 1.95B | 915.70M |
| Free Cash Flow | 8.97B | 3.76B | 792.00M | 5.73B | 6.06B | 5.11B | 3.80B | 4.31B | 4.54B | 3.81B |
This table shows 10 annual periods of Eli Lilly's cash flow statement, from FY 2025 back to FY 2016, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow LLY's reporting calendar. What is a cash flow statement?